Distribution Agreement for Brachytherapy

The seed will be available in the full range of presentation options required by today's brachytherapy programs.

"Oncura has entered into this partnership to ensure that we fully satisfy the needs of all prostate brachytherapy customers,” stated James McGlone, president and CEO, Oncura. "We've increased our long-term commitment to the brachytherapy community and look forward to the opportunity of providing an enhanced level of service; this agreement will allow us to do so.”

The seeds have been supported by dosimetry studies recommended by the American Association of Physicists in Medicine (AAPM). Oncura will provide Prospera as a standard loose seed in their novel Strand, as well as in preloaded needles or Mick cartridges. Added to its range of iodine-125 products, Rapid Strand, OncoSeed, and EchoSeed, the introduction of Prospera will provide increased flexibility and convenience for all prostate brachytherapy programs.





Related Links:
Oncura
North American Scientifics'